Minh Tong Duc
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Minh Tong Duc has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Hoàng Trung Nguyễn
Department of Military Hygiene, Vietnam Military Medical University, Hanoi, Vietnam
3 shared publications Thanh Bui Duc
Department of Surgical Intensive Care, Military Hospital 175, Ho Chi Minh City, Vietnam
2 shared publicationsAnh Le Tuan
Department of Military Hygiene, Vietnam Military Medical University, Hanoi, Vietnam
1 shared publicationBa Van Nguyen
Department of Oncology, Military Hospital 103, Vietnam Military Medical University, Hanoi, Vietnam
1 shared publicationBac Nguyen Thanh
1 shared publicationBinh Huynh Thanh
1 shared publication
Latest Publications
- Open Access
- 1 November 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-18
Beyond the Reach of Standard Prophylaxis: Mycoplasma hominis and Ureaplasma Spp. in Postoperative Urological, Andrological and Renal Transplant Infections
Genital mollicutes, namely Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum, colonize the lower urogenital tract of a substantial minority of healthy adults yet are rarely considered in postoperative urological, andrological or renal transplant infection. This narrative review examines the diagnostic and prophylactic gap they create. Their lack of a cell wall makes Gram staining uninformative and confers intrinsic resistance to beta-lactams and glycopeptides. Routine microbiology also has limited sensitivity: Ureaplasma spp. generally require specialized culture or molecular detection, whereas M. hominis may grow slowly on enriched routine media but is easily overlooked. Reported disease ranges from sterile pyuria and graft pyelonephritis to perinephric or prostatic abscess, encrusting uropathy, recurrent struvite calculi and hyperammonemia syndrome. Commonly recommended perioperative agents provide little or no reliable activity against these organisms. Acquired resistance is strongly regional: among Ureaplasma isolates from North America and Germany, reported resistance to several key agents remains below 8%, whereas Vietnamese surveillance found ciprofloxacin resistance of 76.0% in U. urealyticum and 88.0% in M. hominis; doxycycline and josamycin retained greater activity but were not uniformly active. We propose five pragmatic clinical triggers, compartment-directed sampling and region-aware empiric management while emphasizing that these recommendations rest predominantly on case-level evidence. Prospective surgical studies are needed to define incidence, diagnostic thresholds and the role of screening.
- 1 November 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-18
Open AccessBeyond the Reach of Standard Prophylaxis: Mycoplasma hominis and Ureaplasma Spp. in Postoperative Urological, Andrological and Renal Transplant Infections
Genital mollicutes, namely Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum, colonize the lower urogenital tract of a substantial minority of healthy adults yet are rarely considered in postoperative urological, andrological or renal transplant infection. This narrative review examines the diagnostic and prophylactic gap they create. Their lack of a cell wall makes Gram staining uninformative and confers intrinsic resistance to beta-lactams and glycopeptides. Routine microbiology also has limited sensitivity: Ureaplasma spp. generally require specialized culture or molecular detection, whereas M. hominis may grow slowly on enriched routine media but is easily overlooked. Reported disease ranges from sterile pyuria and graft pyelonephritis to perinephric or prostatic abscess, encrusting uropathy, recurrent struvite calculi and hyperammonemia syndrome. Commonly recommended perioperative agents provide little or no reliable activity against these organisms. Acquired resistance is strongly regional: among Ureaplasma isolates from North America and Germany, reported resistance to several key agents remains below 8%, whereas Vietnamese surveillance found ciprofloxacin resistance of 76.0% in U. urealyticum and 88.0% in M. hominis; doxycycline and josamycin retained greater activity but were not uniformly active. We propose five pragmatic clinical triggers, compartment-directed sampling and region-aware empiric management while emphasizing that these recommendations rest predominantly on case-level evidence. Prospective surgical studies are needed to define incidence, diagnostic thresholds and the role of screening.
- Open Access
- 1 August 2023
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 16, 5535-5546
Predicting Antibiotic Resistance in ICUs Patients by Applying Machine Learning in Vietnam
Introduction: Artificial Intelligence (AI) and machine learning (ML) are used extensively in HICs to detect and control antibiotic resistance (AMR) in laboratories and clinical institutions. ML is designed to predict outcome variables using an algorithm to enable “machines” to learn the “rules” from the data. ML is increasingly being applied in intensive care units to identify AMR and to assist empiric antibiotic therapy. This study aimed to evaluate the performance of ML models for predicting AMR bacteria and resistance to antibiotics in two Vietnamese hospitals. Patients and Methods: A cross-sectional study combined with retrospective was conducted from 1st January 2020 to 30th June 2022. Five models were developed to predict antibiotic resistance of bacterial infections of ICU patients. Two datasets were prepared to predict AMR bacteria and antibiotics with ML models. The performance of the prediction models was evaluated by various indicators (sensitivity, specificity, precision, accuracy, F1-score, PRC, AuROC, and NormMCC) to determine the optimal time point for data selection. Python version 3.8 was used for statistical analyses. Results: The accuracy, F1-score, AuROC, and normMMC of LightGBM, XGBoost, and Random Forest models were higher than those of other models in both datasets. In both datasets 1 and 2, accuracy, F1-score, AuROC and normMCC of the XGBoost model were the highest among five models (from 0.890 to 1.000). Only Random Forest models had specificity scores higher than 0.850. High scores of sensitivity, accuracy, precision, F1-score, and normMCC indicated that the models were making accurate predictions for datasets 1 and 2. Conclusion: XGBoost, LightGBM, and Random Forest were the best-performed machine learning models to predict antibiotic resistance of bacterial infections of ICUs patients using the patients’ EMRs.
- 1 August 2023
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 16, 5535-5546
Open AccessPredicting Antibiotic Resistance in ICUs Patients by Applying Machine Learning in Vietnam
Introduction: Artificial Intelligence (AI) and machine learning (ML) are used extensively in HICs to detect and control antibiotic resistance (AMR) in laboratories and clinical institutions. ML is designed to predict outcome variables using an algorithm to enable “machines” to learn the “rules” from the data. ML is increasingly being applied in intensive care units to identify AMR and to assist empiric antibiotic therapy. This study aimed to evaluate the performance of ML models for predicting AMR bacteria and resistance to antibiotics in two Vietnamese hospitals. Patients and Methods: A cross-sectional study combined with retrospective was conducted from 1st January 2020 to 30th June 2022. Five models were developed to predict antibiotic resistance of bacterial infections of ICU patients. Two datasets were prepared to predict AMR bacteria and antibiotics with ML models. The performance of the prediction models was evaluated by various indicators (sensitivity, specificity, precision, accuracy, F1-score, PRC, AuROC, and NormMCC) to determine the optimal time point for data selection. Python version 3.8 was used for statistical analyses. Results: The accuracy, F1-score, AuROC, and normMMC of LightGBM, XGBoost, and Random Forest models were higher than those of other models in both datasets. In both datasets 1 and 2, accuracy, F1-score, AuROC and normMCC of the XGBoost model were the highest among five models (from 0.890 to 1.000). Only Random Forest models had specificity scores higher than 0.850. High scores of sensitivity, accuracy, precision, F1-score, and normMCC indicated that the models were making accurate predictions for datasets 1 and 2. Conclusion: XGBoost, LightGBM, and Random Forest were the best-performed machine learning models to predict antibiotic resistance of bacterial infections of ICUs patients using the patients’ EMRs.
- Open Access
- 1 January 2023
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 17
Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma
Background: The B-type rafkinase (BRAF) V600E gene mutation plays an important role in the pathogenesis, diagnosis, and prognosis of thyroid carcinoma. This study was conducted to investigate the rate of the BRAF V600E mutation, the relationships between the BRAF V600E gene mutation and some immunohistochemical markers, and recurrence rate in patients with differentiated thyroid cancer. Method: The study was conducted by a descriptive and longitudinal follow-up method on 102 thyroid carcinoma patients at 103 Military Hospital, Hanoi, Vietnam. All patients were identified with the BRAF V600E gene mutation by real-time polymerase chain reaction. Results: The rate of BRAF V600E gene mutation in patients with thyroid cancer was 60.8%. Patients with BRAF V600E gene mutation had a significantly higher rate of positive cyclooxygenase 2 (COX-2) and Ki67 markers than those without the mutation (COX-2: odds ratio [OR] = 2.93; 95% confidence interval [CI] = 1.27-6.74, P = .011; Ki67: OR = 3.41; 95% CI = 1.31-8.88, P = .01). A statistically significant relationship was identified between the rate of BRAF V600E mutation and the rate of positive Hector Battifora mesothelial 1 (HBME-1) (B = −1.040; P = .037) and COX-2 (B = −1.123; P = .023) markers. The recurrence rate in patients with BRAF V600E gene mutation was significantly higher than that in those without the mutation ( P = .007). The mean of the recurrence time of patients with BRAF V600E mutation was significantly lower than that in those without the mutation ( P = .011). Conclusions: A high prevalence of BRAF V600E gene mutation was found in thyroid carcinoma patients. The rates of positive HBME-1, COX-2, and Ki67 markers were significantly correlated to BRAF V600E gene mutation. Patients with BRAF V600E gene mutation showed a significantly higher relapse rate and earlier relapse time than those without the mutation.
- 1 January 2023
- Published by SAGE Publications in Clinical Medicine Insights: Oncology
- Vol. 17
Open AccessRelationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma
Background: The B-type rafkinase (BRAF) V600E gene mutation plays an important role in the pathogenesis, diagnosis, and prognosis of thyroid carcinoma. This study was conducted to investigate the rate of the BRAF V600E mutation, the relationships between the BRAF V600E gene mutation and some immunohistochemical markers, and recurrence rate in patients with differentiated thyroid cancer. Method: The study was conducted by a descriptive and longitudinal follow-up method on 102 thyroid carcinoma patients at 103 Military Hospital, Hanoi, Vietnam. All patients were identified with the BRAF V600E gene mutation by real-time polymerase chain reaction. Results: The rate of BRAF V600E gene mutation in patients with thyroid cancer was 60.8%. Patients with BRAF V600E gene mutation had a significantly higher rate of positive cyclooxygenase 2 (COX-2) and Ki67 markers than those without the mutation (COX-2: odds ratio [OR] = 2.93; 95% confidence interval [CI] = 1.27-6.74, P = .011; Ki67: OR = 3.41; 95% CI = 1.31-8.88, P = .01). A statistically significant relationship was identified between the rate of BRAF V600E mutation and the rate of positive Hector Battifora mesothelial 1 (HBME-1) (B = −1.040; P = .037) and COX-2 (B = −1.123; P = .023) markers. The recurrence rate in patients with BRAF V600E gene mutation was significantly higher than that in those without the mutation ( P = .007). The mean of the recurrence time of patients with BRAF V600E mutation was significantly lower than that in those without the mutation ( P = .011). Conclusions: A high prevalence of BRAF V600E gene mutation was found in thyroid carcinoma patients. The rates of positive HBME-1, COX-2, and Ki67 markers were significantly correlated to BRAF V600E gene mutation. Patients with BRAF V600E gene mutation showed a significantly higher relapse rate and earlier relapse time than those without the mutation.
- 1 June 2022
- Published by Vietnam Military Medical University in VietNam Military Medical Unisversity
- Vol. 47 (5-2022) , 246-258
Clinical characteristics of chiari malformation type I in adults
- 1 June 2022
- Published by Vietnam Military Medical University in VietNam Military Medical Unisversity
- Vol. 47 (5-2022) , 246-258
Clinical characteristics of chiari malformation type I in adults